Agios Pharm Stock Performance
| AGIO Stock | USD 34.54 0.81 2.40% |
The firm shows a Beta (market volatility) of 0.98, which signifies possible diversification benefits within a given portfolio. Agios Pharm returns are very sensitive to returns on the market. As the market goes up or down, Agios Pharm is expected to follow. At this point, Agios Pharm has a negative expected return of -0.32%. Please make sure to confirm Agios Pharm's skewness, and the relationship between the total risk alpha and rate of daily change , to decide if Agios Pharm performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Agios Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 2.4 | Five Day Return (2.32) | Year To Date Return 8.48 | Ten Year Return (69.43) | All Time Return 10.42 |
1 | AGIOs Q3 Earnings Miss Mark, Revenues In Line, Stock Down | 11/01/2024 |
2 | Disposition of 1500 shares by Ballal Rahul D. of Agios Pharm at 59.21 subject to Rule 16b-3 | 11/08/2024 |
3 | Disposition of 300 shares by Foster-cheek Kaye I of Agios Pharm at 32.21 subject to Rule 16b-3 | 11/19/2024 |
4 | TruePKU Initiative Provides Global PKU Community an Opportunity to Share What Its Like to Live with PKU | 12/05/2024 |
5 | Disposition of 200 shares by Scadden David of Agios Pharm at 46.28 subject to Rule 16b-3 | 12/11/2024 |
6 | European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios Mitapivat in Sickle Cell Disease | 12/18/2024 |
7 | Disposition of 8476 shares by Tsveta Milanova of Agios Pharm subject to Rule 16b-3 | 01/03/2025 |
8 | Disposition of 2804 shares by Tsveta Milanova of Agios Pharm at 32.18 subject to Rule 16b-3 | 01/06/2025 |
9 | FDA Accepts Agios Supplemental New Drug Application for PYRUKYN | 01/08/2025 |
10 | Agios Pharmaceuticals, Inc. Receives Average Recommendation of Moderate Buy from Brokerages | 01/10/2025 |
11 | Agios Pharmaceuticals Inc Announces Key Milestones and Strategic Plans for 2025 | 01/13/2025 |
12 | January 17, Feast Day of Agios Antonios O Megas | 01/16/2025 |
13 | Agios Pharmaceuticals Outlines 2025 Milestones in 8-K Filing | 01/21/2025 |
| Begin Period Cash Flow | 139.3 M |
Agios |
Agios Pharm Relative Risk vs. Return Landscape
If you would invest 4,483 in Agios Pharm on November 2, 2024 and sell it today you would lose (1,029) from holding Agios Pharm or give up 22.95% of portfolio value over 90 days. Agios Pharm is currently does not generate positive expected returns and assumes 4.8474% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Agios, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Agios Pharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Agios Pharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Agios Pharm, and traders can use it to determine the average amount a Agios Pharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0659
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AGIO |
Estimated Market Risk
| 4.85 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Agios Pharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Agios Pharm by adding Agios Pharm to a well-diversified portfolio.
Agios Pharm Fundamentals Growth
Agios Stock prices reflect investors' perceptions of the future prospects and financial health of Agios Pharm, and Agios Pharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Agios Stock performance.
| Return On Equity | 0.54 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | 20.51 % | ||||
| Operating Margin | (11.47) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 57.03 M | ||||
| Price To Earning | 1.26 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 59.93 X | ||||
| Revenue | 26.82 M | ||||
| Gross Profit | (266.58 M) | ||||
| EBITDA | (384.86 M) | ||||
| Net Income | (352.09 M) | ||||
| Cash And Equivalents | 819.31 M | ||||
| Cash Per Share | 14.95 X | ||||
| Total Debt | 72 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 17.98 X | ||||
| Book Value Per Share | 28.53 X | ||||
| Cash Flow From Operations | (296.06 M) | ||||
| Earnings Per Share | 11.66 X | ||||
| Market Capitalization | 1.97 B | ||||
| Total Asset | 937.12 M | ||||
| Retained Earnings | (822.65 M) | ||||
| Working Capital | 765.88 M | ||||
| Current Asset | 337.33 M | ||||
| Current Liabilities | 52.89 M | ||||
About Agios Pharm Performance
By examining Agios Pharm's fundamental ratios, stakeholders can obtain critical insights into Agios Pharm's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Agios Pharm is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 659.35 | 532.26 | |
| Return On Tangible Assets | (0.34) | (0.32) | |
| Return On Capital Employed | (0.52) | (0.54) | |
| Return On Assets | (0.34) | (0.32) | |
| Return On Equity | (0.39) | (0.41) |
Things to note about Agios Pharm performance evaluation
Checking the ongoing alerts about Agios Pharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Agios Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Agios Pharm generated a negative expected return over the last 90 days | |
| Agios Pharm has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 26.82 M. Net Loss for the year was (352.09 M) with loss before overhead, payroll, taxes, and interest of (266.58 M). | |
| Agios Pharm currently holds about 819.31 M in cash with (296.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Agios Pharmaceuticals Outlines 2025 Milestones in 8-K Filing |
- Analyzing Agios Pharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Agios Pharm's stock is overvalued or undervalued compared to its peers.
- Examining Agios Pharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Agios Pharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Agios Pharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Agios Pharm's stock. These opinions can provide insight into Agios Pharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share | Quarterly Revenue Growth 0.212 | Return On Assets | Return On Equity |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.